

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets

(11)

Publication number:

**0 251 197**

**A2**

(12)

## EUROPEAN PATENT APPLICATION

(21)

Application number: 87109117.9

(51)

Int. Cl.4: **C07G 3/00**, **C07H 13/08**,  
**A61K 31/72**

(22)

Date of filing: 25.06.87

(30)

Priority: 01.07.86 IT 4820886

(43)

Date of publication of application:  
07.01.88 Bulletin 88/01

(84)

Designated Contracting States:  
AT BE CH DE ES FR GB GR IT LI LU NL SE

(71)

Applicant: Sigma-Tau Industrie  
Farmaceutiche Riunite S.p.A.  
47, Viale Shakespeare  
I-00144 Rome(IT)

Applicant: IVERNI DELLA BEFFA S.p.A.  
Via Ripamonti, 99  
I-20141 Milan(IT)

(72)

Inventor: Foresta, Piero  
Viale Shakespeare, 47  
I-00144 Rome(IT)  
Inventor: Ghirardi, Orlando  
Viale Shakespeare, 47  
I-00144 Rome(IT)  
Inventor: Gabetta, Bruno  
Via Ripamonti, 99  
I-20141 Milan(IT)  
Inventor: Cristoni, Aldo  
Via Ripamonti, 99  
I-20141 Milan(IT)

(74)

Representative: Minoja, Fabrizio  
Studio Consulenza Brevettuale Via Rossini,  
8  
I-20122 Milano(IT)


(54)

Triterpene saponins having anti-inflammatory, mucolytic and antiedemic activities, process for the preparation thereof and pharmaceutical compositions containing them.

(57)

Triterpene saponins of formula


**EP 0 251 197 A2**



wherein  $R_1$  is H or OH and  $R_2$  is a tetrasaccharide, or alternatively pentasaccharide, chain have antiinflammatory, mucolytic and antiedemic activities. Said saponins are isolated from roots and bark of *Crossopteryx febrifuga*, for instance by precipitating them, in form of a complex with cholesterol or sytosterol, from an alcoholic extract of the vegetal material and by partitioning the precipitate between an apolar solvent, which subtracts the complexing agent and a polar solvent in which saponins are soluble.

**TRITERPENE SAPONINS HAVING ANTI-INFLAMMATORY, MUCOLYTIC AND ANTIEDEMIC ACTIVITIES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM**

The present invention relates to two novel triterpene saponins, having antiinflammatory, mucolytic and antiedemic activity, of general formula



wherein:

R<sub>1</sub> is H or OH, and

20 R<sub>2</sub> is a tetrasaccharide residue having 573 mass unities or, alternatively, a pentasaccharide residue having 705 mass unities, linked by means of an ester bond to the C-28 carboxyl.

For sake of shortness, the saponin wherein R<sub>1</sub> is H will be designated "Crossoptine A", whilst the saponin wherein R<sub>1</sub> is OH will be designated "Crossoptine B". The term "Crossoptine" is used since saponins of formula I may be isolated from roots and bark of Crossopteryx febrifuga, by means of a process which is another object of the present invention.

The present invention further relates to pharmaceutical compositions, particularly for topical administration, containing as the active ingredient one of the above cited Crossoptines, for the treatment of inflammatory and oedema conditions.

30 As it is clear from formula (I), Crossoptine A and Crossoptine B belong to the group of oleanolic acid saponins, and are characterized by the presence of alcohol residues at the 2 $\beta$ , 3 $\beta$ , 6 $\beta$  and 23 positions and, in the case of Crossoptine B, also at the 16 $\alpha$  position.

Crossoptines contain two saccharidic groups, consisting of a D-glucose residue, which is bound to the hydroxyl group at the 3-position and, as already mentioned, by a tetrasaccharide (573 mass units) or, alternatively, a pentasaccharide (705 mass units), connected to the C-28 carboxyl by an ester bond.

35 According to the structures of general formula I, mass spectrometry (FAB) revealed for Crossoptine A molecular weight of 1222 (R<sub>2</sub> = tetrasaccharide); for Crossoptine B the HPLC analysis combined with mass spectrometry revealed the presence of two saponins in 1:1 ratio having molecular weight 1238 (R<sub>2</sub> = tetrasaccharide) and 1370 (R<sub>2</sub> = pentasaccharide). Crossopteryx febrifuga is a plant with a shrub-type growth found all round the African tropical belt.

40 The therapeutic activity of crude extracts from bark, roots and leaves of Crossopteryx febrifuga is already known in african folk medicine, particularly the antipyretic activity - which gives the plant the name -, although the plant is known to have other various therapeutic applications. Depending on the areas and the traditions therein prevailing, antelmintic activity, antidote activity against some poisons, and activity against chicken-pox, vertigo, syncope, stomach-ache, conjuntivitis or venereal diseases are attributed to Crossopteryx febrifuga.

The various source agree in considering Crossopteryx febrifuga active as an antipyretic agent.

These indications have been merely empiric, since no characterized product having a high and steady activity, or a reproducible process for its preparation were available, that could allow to verify its effective pharmacodynamic action from a rigorously quantitative point of view.

50

The isolation of the active principles, on the other hand, allowed not only the possibility to carry out serious researches on its pharmacological effects, but also to detect its antiedemic analgesic and mucolytic activity, and the extraction of Crossoptine A and Crossoptine B from vegetal material may be carried out by means of alcohols having 1 to 3 carbon atoms, or aliphatic ketones and mixtures thereof with water. Hot-extraction of the drug with aqueous 80% methanol or ethanol is generally preferred.

The obtained extracts, after concentration under vacuum, are filtered to remove waxy materials, then they are subjected to counter-extraction with solvents having low polarity (hydrocarbons, chlorinated solvents, ethyl acetate, etc.) in order to remove the lipid components.

The purified aqueous solution may be then treated according to two alternative processes.

According to a first process (process A) the solution is diluted with alcohols or water-miscible ketones to an about 50% concentration, and treated at ebullition with a 3- $\beta$  -hydroxysterol excess (e.g. cholesterol or beta-sytosterol). Crossoptines A and B selectively form, with respect to the other extract components, insoluble complexes which are recovered by filtration and purified from any sterol excess by means of washing at room temperature with an hydrocarbon (e.g. n-heptane, toluene, etc.).

The complexes may be thereafter cleaved by partition between an apolar solvent (such as ethyl acetate or chloroform), which subtracts the complexing sterol, and a polar solvent (e.g. 50% aqueous methanol or acetone), in which Crossoptines A and B are soluble.

According to this procedure, a mixture of the two Crossoptines, substantially free from other extract components, may be obtained.

According to the second process (process B), the purified aqueous solution is extracted, together with other polar components, with water-immiscible alcohols (butyl alcohol, amyl alcohols, etc.). After concentration of the alcohol phase, a mixture of the two saponins having a sufficient purity grade is precipitated by dilution with apolar solvents (esters, chlorinated solvents, etc.).

The mixture of Crossoptine A and Crossoptine B, obtained by means of one of the above processes, may be finally separated into the two components by a chromatographic process on silica gel column, eluting with mixtures of chlorinated solvents, alcohols and water in appropriate ratios (for example chloroform-methanol-water in a 14:6:1 v/v ratio or in a 30:10:1 v/v ratio) or, where process A is used, also by simple fractional crystallization from isopropyl alcohol as such or in admixture with other alcohols.

The following non-limiting examples illustrate the extraction and isolation procedures for Crossoptines A and B.

### EXAMPLE 1

#### Isolation of Crossoptine A and B in form of complexes with cholesterol (Process A)

2 kg of finely ground dry root of Crossopteryx febrifuga were extracted in a percolator with 6 l of 80% aqueous methanol for 5 times, under slight reflux. The combined percolates were filtered, then concentrated to 0.6 l under vacuum at a temperature not higher than 40°C.

The methanol concentrate was extracted 3 times with 0.6 l of n-hexane. The hexane phase, containing oily residues, was removed; the methanol phase, after distillation of hexane under vacuum, was diluted with methanol to 1 l, then with 1 l of water, and heated to 50° C under strong stirring. 30 g of cholesterol were added portionwise to the mixture, keeping subsequently the suspension under stirring for 4 hours. The suspension was cooled and left to stand overnight at room temperature.

The complex of saponins with cholesterol was filtered and dried under vacuum for 24 hours, at a temperature of 60°C. 60 g of product were obtained, which was treated with 200 ml of toluene, left under stirring for 3 hours at room temperature, then filtered. After drying at 80°C during a night, 32 g of product were obtained which, by HPLC analysis, proved to consist of 5 g of Crossoptine A and 15 g of Crossoptine B, complexed with 12 g total of cholesterol.

### EXAMPLE 2



**PHARMACOLOGICAL TESTS****(a) Acute toxicity (LD<sub>50</sub>)**

5        Crossoptine A showed a LD<sub>50</sub> by oral route of 350 mg/kg in the rat and Crossoptine B showed a LD<sub>50</sub> of 14 mg/kg by intraperitoneal route and 450 mg/kg by oral route, in the rat.

      Crossoptines A and B proved to have antinflammatory, antiedemic, analgesic and mucokynetic activities, in various pharmacological tests.

10

**(b) Antioedema activity (carrageenin oedema test)**

      Antioedema activity was evaluated in the test of carrageenin oedema on rat paw, after oral and topical administration. The obtained results, in comparison with known active drugs, are reported in table 1.

15

20

25

30

35

40

45

50

55

TABLE\_1 - Antiinflammatory activity of Crossoptine A and B in the carrageenin oedema in the rate

Compound	Dose mg/kg os	N° of animals	% inhibition in comparison with controls				
			1 hour	2 hours	3 hours	4 hours	5 hours
Crossoptine A	100	10	-85°	-81°	-81°	-70°	-53°
Crossoptine B	100	10	-88°	-104°	-93°	-81°	-58°
ASA	200	8	-51°	-39°	-52°	-45°	-42°
Phenylbutazone	100	8	-38°	-30°	-58°	-54°	-47°
Escine	50 <sup>a</sup>	10	-39°	-44°	-51°	-49°	-35°

°°  $p \leq 0.01$  °  $p \leq 0.05$

a) maximal non-diarrhoic dose

(c) Analgesic activity (phenylquinone writhing test)

Crossoptines A and B proved to have an analgesic activity, in the phenylquinone writhing, comparable to that of acetylsalicylic acid (ASA). (Table 2)

**TABLE 2\_** - Analgesic activity of Crossoptines A and B in phenylquinone writhing test in the mouse.

Compound	Dose mg/kg os	N. of animals	% Variation in comparison with controls
Crossoptine A	50 100	10 10	- 31 - 49
Crossoptine B	50 100	10 10	- 38 <sup>°°</sup> - 36 <sup>°</sup>
ASA	50 100	10 10	- 31 <sup>°°</sup> - 32 <sup>°°</sup>

<sup>°°</sup>  $p \leq 0.01$       <sup>°</sup>  $p \leq 0.05$

(d) Mucolytic activity

Crossoptine B, orally administered to the mouse in single and repeated doses, caused an increase in mucus excretion ranging from 48 to 70%. Comparison tests with control compounds (Bromhexine and Sobrerol) are reported also in table 3.



**TABLE 3** - Expectorant activity of Crossoptine B in the mouse.

6

10

15

20

25

Compound	Dose mg/kg	N. of animals	% increase of sodium fluorescein excretion in comparison with controls
Crossoptine A	50 x 1	6	+ 47°°
Crossoptine B	50 x 5	10	+ 73°°
Bromhexin	75 x 1	10	+ 48°°
Sobrerol	150 x 1	10	+ 67°°

°°  
p ≤ 0.01

30 (e) DHT test (delayed - type hypersensitivity)

Male BDF<sub>1</sub> mice weighing 22-26 g were used in this delayed hypersensitivity test.

The procedure was the following:

35 0.2 ml of SRBC at a concentration of  $5 \times 10^7$  cell/ml in phosphate buffer ( $1 \times 10^7$  cell/mouse) (sensitizing injection) were administered subcutaneously in the front dorsal area of BDF<sub>1</sub> mice, divided into as many groups of 10 animals each as many were the administered doses of the compound under test, one group being the control.

The treated animals received the compounds dissolved in physiological saline, by intraperitoneal route, the day before, the same day and the day after the sensitizing injection.

40 The control animals received, instead of the compound under test, the only solvent used to dissolve said compound.

4 days after the sensitizing injection, 50 ml of SRBC at a concentration of  $2 \times 10^8$  cell/ml ( $1 \times 10^8$  cell/mouse) (challenge injection) were administered into the rear sx paw pad of the mice.

45 24 hours after the challenge injection the animals were killed by cervical dislocation, rear paws were cut at the base and the differences in weight between sx paw (treated with the challenge injection) and the controlateral one were measured.

The weight differences between treated and controlateral control paws of each animals were evaluated, the obtained differences were valuated and standard error and significance of the results were calculated according to Dunnett's test.

50

55

**TABLE 4** - Effect of the compound administered by intraperitoneal route on the delayed hypersensitivity reaction in the mouse (DTH)

Compound	Dose (mg/kg <sup>-1</sup> )	Administration time with respect to hypersensitization (days)	Weight difference ( $\bar{m}g \pm E.S.$ ) between treated and control lateral paws
Control	-	-	51.75 $\pm$ 7.67
Crossoptine A	1	-1 0 +1	42.37 $\pm$ 4.39
Crossoptine A	10	-1 0 +1	19.42 $\pm$ 3.54 <sup>▲</sup>
Control	-	-	38.87 $\pm$ 2.68
Crossoptine A (ripetition)	10	-1 0 +1	25.62 $\pm$ 3.37 <sup>▲</sup>
Control	-	-	40.20 $\pm$ 3.62
Crossoptine B	1	-1 0 +1	32.80 $\pm$ 3.97
Crossoptine B	10	-1 0 +1	23.40 $\pm$ 1.76 <sup>▲</sup>

<sup>▲</sup> :  $p \leq 0.01$  (Dunnett's test)

The above results prove that the novel triterpene saponins (I) are useful therapeutic agents, particularly antiinflammatory agents for the treatment of phlogosis of various etiology and mucolytic agents in the treatment of acute and chronic bronchitis having an inflammatory component.

Compounds (I) may be formulated in common pharmaceutical formulations, according to pharmaceutical techniques which are well known to the skilled in the art.

Some compositions according to the invention are reported hereinafter.

Formulation of a ointment containing 1% of Crossoptine B Crossoptine B 1 g

Excipients: Polyethylene glycol 2000 fatty acids esters 2 g  
 Polysorbate 80 3 g  
 Cetyl alcohol 10 g  
 Wheat germ oil 2 g  
 Silicon oil 350 CPS 0.5 g  
 Methyl and propyl p-oxybenzoate-mixture 0.2 g  
 Butylhydroxyanisol 0.05 g  
 Sodium ethylenediamino-tetraacetate 0.02 g  
 Carboxyvinylpolymer (Carbopol 934) 0.8 g  
 Triethanolamine 1.2 g  
 Perfumed composition 0.2 g  
 Depurated water q. s. to 100 g


65.

Formulation of 100 mg tablets containing 20 mg of Crossoptine B Crossoptine B 20 mg

Excipients: Malze starch 40 mg  
 Lactose 26 mg  
 Polyvinylpyrrolidone 5 mg  
 Silica powder 3 mg  
 5 Carboxymethyl-starch 3 mg  
 Magnesium stearate 2 mg  
 Talc 1 mg

## Claims

### 1. Triterpene saponins of general formula



wherein:

$R_1$  is H or OH, and

$R_2$  is a tetrasaccharide residue having 573 mass units or, alternatively, a pentasaccharide residue having 705 mass units, linked by means of an ester bond to the C-28 carboxyl.

2. Crossoptine A.

3. Crossoptine B.

4. A process for isolating triterpene saponins of general formula (I) from an aqueous solution obtained by means of known procedures, from a C-C<sub>3</sub> alcohol or aliphatic ketone extract of root and bark of Crossopteryx febrifuga, which process comprises:

(a) treating the solution at ebollition with a 3-beta-hydroxysterol, to selectively precipitate said triterpene saponins in form of complexes, said complexes being separated and purified;

(b) cleaving said complexes by partition by contacting them with a mixture of an apolar solvent in which 3-beta-hydroxysterol is selectively soluble and of a polar solvent in which triterpene saponins are selectively soluble.

5. A process according to claim 4, which further comprises the step:

(c) separating Crossoptine A from Crossoptine B by chromatography on Silica gel, eluting with mixtures of chlorinated solvents and hydro-alcoholic mixtures.

6. A process according to claim 4, which further comprises the step:


(c') separating Crossoptine A from Crossoptine B by fractional crystallization from isopropanol.

7. A process according to claim 4, wherein the 3-beta-hydroxysterol is selected from cholesterol and beta-sytosterol, the apolar solvent is selected from ethyl acetate and chloroform and the polar solvent is selected from methanol and an acetone aqueous solution.

8. Pharmaceutical compositions having antiinflammatory, antiedemic, analgesic and mucolytic activities, for oral or topical administration, comprising a triterpene saponin of general formula (I) and a pharmacologically acceptable excipient.

Claims for the following Contracting States : SP, GR

1. A process for the preparation of triterpene saponins of general formula:



wherein:

20  $R_1$  is H or OH, and

$R_2$  is a tetrasaccharide residue having 573 mass units or, alternatively, a pentasaccharide residue having 705 mass units, linked by means of an ester bond to the C-28 carboxyl, from an aqueous solution obtained by means of known procedures, from a  $C_7$ - $C_8$  alcohol or aliphatic ketone extract of root and bark of Crossopteryx febrifuga, which process comprises:

25 (a) treating the solution at ebollition with a 3-beta-hydroxysterol, to selectively precipitate said triterpene saponins in form of complexes, said complexes being separated and purified;

(b) cleaving said complexes by partition by contacting them with a mixture of an apolar solvent in which 3-beta-hydroxysterol is selectively soluble and of a polar solvent in which triterpene saponins are selectively soluble.

30 2. A process according to claim 1, which further comprises the step:

(c) separating Crossoptine A from Crossoptine B by chromatography on Silica gel, eluting with mixtures of chlorinated solvents and hydro-alcoholic mixtures.

3. A process according to claim 1, which further comprises the step:

(c) separating Crossoptine A from Crossoptine B by fractional crystallization from isopropanol.

35 4. A process according to claim 1, wherein the 3-beta-hydroxysterol is selected from cholesterol and beta-sytosterol, the apolar solvent is selected from ethyl acetate and chloroform and the polar solvent is selected from methanol and an acetone aqueous solution.

40

45

50

55